title: Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics.
abstract: BACKGROUND
  Clinical trials have demonstrated the efficacy of golimumab (GLB) in improving the signs and symptoms of psoriatic arthritis (PsA).
  
  
  OBJECTIVE
  The aim of this study was to evaluate the efficacy of GLB in monotherapy in patients affected by PsA with cutaneous involvement unresponsive to other anti-tumor necrosis factor-α (TNF-α) agents.
  
  
  METHODS
  This study included 32 patients treated with GLB as monotherapy, at a dosage of 50 mg, subcutaneously, every 4 weeks. Patients were divided into 3 groups (A, B, and C) according to their number of previous anti-TNF-α treatments (1, 2, or 3). Clinical and laboratory evaluations were performed at weeks 0, 12, and 24.
  
  
  RESULTS
  All patients showed significant improvement of their clinical, inflammatory, and quality of life indexes.
  
  
  CONCLUSIONS
  Data suggest that GLB can be successful and safe in patients affected by PsA with skin involvement previously treated with other anti-TNF-α agents.
authors.affiliation: Rheumatology, Allergology and Clinical Immunology, University of Rome 'Tor Vergata', Rome, Italy.
authors.forename: Maria Sole
authors.initials: MS
authors.lastname: Chimenti
authors.forename: Miriam
authors.initials: M
authors.lastname: Teoli
authors.forename: Rosita
authors.initials: R
authors.lastname: Saraceno
authors.forename: Annunziata
authors.initials: A
authors.lastname: Dattola
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ventura
authors.forename: Andrea
authors.initials: A
authors.lastname: Chiricozzi
authors.forename: Carlo
authors.initials: C
authors.lastname: Chiaramonte
authors.forename: Roberto
authors.initials: R
authors.lastname: Perricone
authors.forename: Sergio
authors.initials: S
authors.lastname: Chimenti
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001685:Biological Factors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001685:Biological Factors; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab